Taysha Gene Therapies (TSHA) Operating Leases (2022 - 2026)

Taysha Gene Therapies (TSHA) has 5 years of Operating Leases data on file, last reported at $17.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 3.94% year-over-year to $17.8 million; the trailing twelve-month figure through Mar 2026 stood at $17.8 million (up 3.94% YoY), and the FY2025 full-year result was $18.2 million, up 4.67% from the prior year.
• Operating Leases slipped to $17.8 million in Q1 2026, from $18.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $20.4 million in Q4 2022 to a low of $16.5 million in Q3 2025.
• A 5-year average of $18.3 million and a median of $18.2 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases decreased 8.4% in 2024 and climbed 4.67% in 2025, its largest moves.
• Tracing TSHA's Operating Leases over 5 years: stood at $20.4 million in 2022, then slipped by 7.27% to $19.0 million in 2023, then dropped by 8.4% to $17.4 million in 2024, then advanced by 4.67% to $18.2 million in 2025, then dropped by 2.23% to $17.8 million in 2026.
• Business Quant data shows TSHA's Operating Leases at $17.8 million in Q1 2026, $18.2 million in Q4 2025, and $16.5 million in Q3 2025.